Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Published pivotal FRONTIER2 study showed investigational denecimig significantly reduced annualized bleeding rate compared to prior clotting factor prophylaxis and on-demand treatment in people with hemophilia A, with or without inhibitors1 The study evaluated the efficacy and safety of...